Beyond Fragmentation: How Inotiv’s Unified Toxicology Network Accelerates Drug Development
In today’s increasingly complex drug development landscape, the last thing innovators need is fragmentation in their preclinical studies. Toxicological assessment must be seamless, insightful, and predictive.
At Inotiv, our strategic vision for toxicology is centered on a powerful advantage: providing integrated toxicology services through a single, coordinated network of scientific excellence. This unified approach removes complexity, standardizes quality across all sites, and ensures you receive the most valuable, actionable data possible.
To drive this vision forward and ensure this superior client experience, I, Noel D. Horton, have accepted the challenge of leading this charge as the new Executive Director of Toxicology.
A New Era of Unified Scientific Leadership
Our primary goal is to drive alignment, scientific excellence, and a unified client experience across all our sites.
In this role, I will lead the integration of toxicology across our entire DSA organization, focusing on five key priorities that translate directly into tangible benefits for Inotiv's clients:
- Integrated Functions: We ensure your program runs through a single, cohesive network of shared best practices, eliminating site-to-site variability.
- Elevated Expertise: We invest in our scientific bench, so you always access the collective knowledge of Inotiv’s top experts through mentorship and collaboration.
- Standardized Quality: We guarantee consistent, high-quality execution and reporting across all studies, essential for regulatory success.
- Fostered Collaboration: We actively connect key functions like Toxicology, Pathology, and DMPK to provide YOU, the client, with a stronger, multidisciplinary approach.
- Accountability & Transparency: We establish a trusting relationship by owning our work, ensuring open communication, and proactively addressing any challenges.
The Inotiv Advantage: Accessible, Consistent, Accountable
This unified approach is delivered through three core commitments that set Inotiv apart:
• Accessible and Collaborative Expertise
We believe the best toxicology studies begin with a conversation. We offer convenient, direct access to our scientists—not just project managers—who are eager to optimize your study design from day one. We ensure that every study is maximized for data value and tailored precisely to your regulatory path.
• Consistent Quality Across All Sites
Consistency is the bedrock of reliable data. By integrating our functions, we are establishing a single network with unified standards across all sites (see our Global Locations). Our goal is to deliver the same seamless interactions and superior study conduct every time, ensuring high-quality, reproducible results.
• Accountable and Transparent Service
We own our work, which is why accountability is central to our client experience. We are committed to transparency in every phase of your program. When challenges arise, we work with you immediately to implement corrective measures and prevent recurrence, fostering trust throughout your program’s lifecycle.
Meet the Leader:
My background, spanning both the sponsor and CRO side, provides the translational insight necessary to lead this integration effectively.
• Scientific Credibility (DABT): As a Diplomate of the American Board of Toxicology (DABT) since 1999, I bring a recognized standard of scientific rigor.
• Translational Perspective: Experience from both the sponsor side (Pfizer and Eli Lilly and Company) and the CRO side (MPI Research/Charles River Laboratories) helps me bridge the gap between discovery and regulatory success for our clients.
• Regulatory Command: My experience as a Study Director and former IACUC Chair ensures ethical and compliant study conduct.
Ready to discuss your program with a unified team of experts? Contact us today to learn how Inotiv’s integrated toxicology network can accelerate your next drug discovery milestone.
